[The effect of cerebrocrast on erythrocyte function].

Abstract

The new calcium antagonist cerebrocrast intravenously infused in a dose of 0.4 micrograms.kg-1.min-1 during 15 min prevented erythrocyte deformability disturbances at the end of cerebral ischemia in rats, which was induced by carotid artery occlusion during 30 min. The agents also prevented the deformability 1 hour after the onset of recirculation. Cerebrocrast reduced spontaneous erythrocyte aggregation, the strength of erythrocytic aggregates, and hemoglobin affinity for oxygen. The latter effect was associated with the drug-induced increase in erythrocytic 2,3-diphosphoglycerate levels.

• Authors: T M Plotnikova, N N Firsov, A S Saratikov
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 1993 May-Jun Vol. 56 Issue 3 Pg. 35-7 ISSN: 0869-2092 [Print] Russia (Federation)
• Vernacular Title: Vliianie tserebrokrasta na funktsional'noe sostoianie éritrotsitov.
• PMID: 8219988 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Calcium Channel Blockers
• Dihydropyridines
• Oxyhemoglobins
• 2,6-dimethyl-3,5-bis(2'-propoxyethoxycarbonyl)-4-(2''-difluoromethoxyphenyl)-1,4-dihydropyridine

Topics

• Animals
• Calcium Channel Blockers (pharmacology, therapeutic use)
• Dihydropyridines (pharmacology, therapeutic use)
• Drug Evaluation, Preclinical
• Erythrocyte Aggregation (drug effects)
• Erythrocyte Deformability (drug effects)
• Erythrocytes (drug effects, physiology)
• Hydrogen-Ion Concentration
• Ischemic Attack, Transient (blood, drug therapy)
• Male
• Oxyhemoglobins (drug effects, metabolism)
• Rats
• Time Factors